MYO7A_HUMAN,E1750L,0.827,Altered Disordered interface (Pr = 0.32 | P = 6.9e-03); Loss of Helix (Pr = 0.31 | P = 2.9e-03); Gain of Proteolytic cleavage at W1745 (Pr = 0.13 | P = 0.03), None,-
MYO7A_HUMAN,E1750S,0.696,Altered Disordered interface (Pr = 0.38 | P = 4.5e-03); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000053|ELME000136|ELME000153|ELME000159,-
MYO7A_HUMAN,Q1754S,0.671,, ELME000085|ELME000146|ELME000239,-
MYO7A_HUMAN,K1759P,0.608,Loss of Helix (Pr = 0.27 | P = 0.03), ELME000045|ELME000106|ELME000146,-
MYO7A_HUMAN,L1760I,0.038,-,-,-
MYO7A_HUMAN,S1763A,0.155,-,-,-
MYO7A_HUMAN,E1765L,0.660,, ELME000053|ELME000202,-
MYO7A_HUMAN,L1766Q,0.816,Gain of B-factor (Pr = 0.27 | P = 0.01), ELME000053|ELME000202,-
MYO7A_HUMAN,S1767V,0.381,-,-,-
MYO7A_HUMAN,Q1768P,0.844,, ELME000136|ELME000159|ELME000202,-
MYO7A_HUMAN,E1769S,0.479,-,-,-
MYO7A_HUMAN,L1772M,0.055,-,-,-
MYO7A_HUMAN,L1772W,0.615,, None,-
MYO7A_HUMAN,A1773G,0.553,, None,-
MYO7A_HUMAN,A1776T,0.652,Gain of Allosteric site at Y1780 (Pr = 0.25 | P = 0.01); Gain of Acetylation at K1779 (Pr = 0.20 | P = 0.04), ELME000041,-
MYO7A_HUMAN,V1777I,0.190,-,-,-
MYO7A_HUMAN,V1777M,0.200,-,-,-
MYO7A_HUMAN,R1788G,0.832,Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Ubiquitylation at K1787 (Pr = 0.16 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04); Gain of Sulfation at Y1784 (Pr = 0.01 | P = 0.05), ELME000052|ELME000063|ELME000064|ELME000065|ELME000100|ELME000108|ELME000271|PS00005,-
MYO7A_HUMAN,P1803S,0.645,Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Allosteric site at F1800 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000336|PS00005|PS00008,-
MYO7A_HUMAN,L1804V,0.433,-,-,-
MYO7A_HUMAN,L1837F,0.876,Gain of Allosteric site at W1834 (Pr = 0.19 | P = 0.05), ELME000149|ELME000335,-
MYO7A_HUMAN,C1840N,0.934,, None,-
MYO7A_HUMAN,N1848S,0.258,-,-,-
MYO7A_HUMAN,N1848T,0.440,-,-,-
MYO7A_HUMAN,L1858V,0.386,-,-,-
MYO7A_HUMAN,K1862P,0.674,Loss of Helix (Pr = 0.27 | P = 0.04), ELME000102|ELME000155|ELME000233|ELME000336|PS00005,-
MYO7A_HUMAN,P1865L,0.473,-,-,-
MYO7A_HUMAN,A1867S,0.279,-,-,-
MYO7A_HUMAN,I1868V,0.055,-,-,-
MYO7A_HUMAN,Q1875H,0.536,Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,A1877V,0.460,-,-,-
MYO7A_HUMAN,L1878F,0.591,Gain of Loop (Pr = 0.29 | P = 9.6e-03); Gain of Allosteric site at R1883 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K1876 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.02); Altered Coiled coil (Pr = 0.14 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000134|ELME000313,-
MYO7A_HUMAN,S1882A,0.187,-,-,-
MYO7A_HUMAN,F1916V,0.871,Altered Metal binding (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.18 | P = 0.01), None,-
MYO7A_HUMAN,S1921D,0.640,Altered Metal binding (Pr = 0.34 | P = 6.7e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03), PS00005,-
MYO7A_HUMAN,I1931Q,0.843,Altered Metal binding (Pr = 0.25 | P = 0.03), ELME000052|ELME000149|ELME000313,-
MYO7A_HUMAN,A1932F,0.695,, ELME000052|ELME000313,-
MYO7A_HUMAN,L1936P,0.812,Altered Stability (Pr = 0.27 | P = 6.7e-03), ELME000052|ELME000106|ELME000146|ELME000239|ELME000313,-
MYO7A_HUMAN,L1937V,0.636,, ELME000052|ELME000053|ELME000106|ELME000146|ELME000313,-
MYO7A_HUMAN,K1938S,0.594,, ELME000053|ELME000064|ELME000146|ELME000313|ELME000333|ELME000336|PS00006,-
MYO7A_HUMAN,E1941D,0.336,-,-,-
MYO7A_HUMAN,E1941G,0.765,, ELME000053|ELME000085|ELME000197|ELME000336|ELME000337,-
MYO7A_HUMAN,G1942T,0.918,, ELME000052|ELME000053|ELME000063|ELME000197,-
MYO7A_HUMAN,V1947S,0.903,Altered Stability (Pr = 0.33 | P = 4.4e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000063,-
MYO7A_HUMAN,I1949Q,0.900,Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
MYO7A_HUMAN,V1956I,0.227,-,-,-
MYO7A_HUMAN,I1979V,0.063,-,-,-
MYO7A_HUMAN,I1983V,0.131,-,-,-
MYO7A_HUMAN,L2059M,0.104,-,-,-
MYO7A_HUMAN,S2073A,0.281,-,-,-
MYO7A_HUMAN,L2103V,0.149,-,-,-
MYO7A_HUMAN,D2142V,0.589,Loss of Relative solvent accessibility (Pr = 0.43 | P = 4.9e-04); Altered Metal binding (Pr = 0.30 | P = 4.0e-03); Altered Ordered interface (Pr = 0.30 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.7e-04), ELME000148|ELME000333|ELME000335|PS00006,-
MYO7A_HUMAN,D2147A,0.462,-,-,-
MYO7A_HUMAN,P2153R,0.842,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.1e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), ELME000053|ELME000062|PS00005,-
MYO7A_HUMAN,F2154D,0.968,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.7e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000220|PS00006,-
MYO7A_HUMAN,F2154W,0.909,Altered Ordered interface (Pr = 0.33 | P = 7.9e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.0e-04); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053,-
MYO7A_HUMAN,I2157L,0.724,Altered Ordered interface (Pr = 0.34 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), None,-
MYO7A_HUMAN,S2158G,0.688,Altered Stability (Pr = 0.34 | P = 4.1e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|PS00008,-
MYO7A_HUMAN,N2159S,0.593,Altered Transmembrane protein (Pr = 0.27 | P = 4.9e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Stability (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|PS00001,-
MYO7A_HUMAN,G2163R,0.731,Loss of Loop (Pr = 0.31 | P = 5.7e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000062|ELME000063|ELME000070|ELME000085|PS00005,-
MYO7A_HUMAN,T2165A,0.770,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.03), ELME000053,-
MYO7A_HUMAN,I2169K,0.971,Gain of Loop (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Stability (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,I2169T,0.938,Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Stability (Pr = 0.21 | P = 0.01); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,L2186P,0.922,Loss of Helix (Pr = 0.31 | P = 3.0e-03); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000136|ELME000147|ELME000159|ELME000336,-
MYO7A_HUMAN,Y2188S,0.819,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.16 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000063|ELME000147|ELME000148|ELME000317|PS00006,-
MYO7A_HUMAN,K2189A,0.774,Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000148|ELME000317,-
MYO7A_HUMAN,D2191E,0.311,-,-,-
MYO7A_HUMAN,T2195C,0.723,Altered Disordered interface (Pr = 0.56 | P = 3.8e-04); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000052|ELME000053|ELME000148|ELME000336,-
MYO7A_HUMAN,Y2197D,0.921,Gain of Intrinsic disorder (Pr = 0.44 | P = 4.7e-03); Altered Disordered interface (Pr = 0.36 | P = 7.6e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,T2203P,0.768,Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Gain of Methylation at K2207 (Pr = 0.09 | P = 0.04), ELME000239,-
MYO7A_HUMAN,A2204T,0.232,-,-,-
MYO7A_HUMAN,M2205W,0.717,Loss of Intrinsic disorder (Pr = 0.59 | P = 1.9e-03); Altered Disordered interface (Pr = 0.33 | P = 6.1e-03); Altered DNA binding (Pr = 0.17 | P = 0.03); Loss of Methylation at K2207 (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,Q2208S,0.718,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered DNA binding (Pr = 0.29 | P = 2.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.04); Gain of Methylation at K2207 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000336,-
MYO7A_HUMAN,G2210S,0.153,-,-,-
MYO7A_HUMAN,G2214K,0.268,-,-,-
MYO7A_HUMAN,G2214N,0.195,-,-,-
MYO7A_HUMAN,V1372G,0.887,Gain of Allosteric site at Y1368 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Altered Stability (Pr = 0.12 | P = 0.03), ELME000137,-
MYO7A_HUMAN,L728P,0.972,Altered Stability (Pr = 0.61 | P = 9.6e-04); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.01); Altered Coiled coil (Pr = 0.21 | P = 0.02); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000146,-
MYO7A_HUMAN,K400N,0.897,Loss of Acetylation at K400 (Pr = 0.40 | P = 1.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Loss of Allosteric site at D396 (Pr = 0.25 | P = 0.01); Loss of Catalytic site at R395 (Pr = 0.08 | P = 0.05), ELME000095|ELME000122,-
MYO7A_HUMAN,P1225L,0.519,Loss of Loop (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.22 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000007,-
MYO7A_HUMAN,S1176N,0.508,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of Disulfide linkage at C1173 (Pr = 0.12 | P = 0.04), ELME000053,-
MYO7A_HUMAN,P503L,0.725,Gain of Helix (Pr = 0.29 | P = 0.02); Gain of Allosteric site at K502 (Pr = 0.19 | P = 0.04), None,-
MYO7A_HUMAN,A230V,0.873,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 2.9e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Allosteric site at I227 (Pr = 0.27 | P = 5.8e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000002|PS00008,-
MYO7A_HUMAN,Q1369H,0.805,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.25 | P = 0.04); Gain of Allosteric site at Y1368 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000020|ELME000120,-
MYO7A_HUMAN,G163R,0.937,Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of Allosteric site at E159 (Pr = 0.26 | P = 7.7e-03); Loss of Methylation at K164 (Pr = 0.22 | P = 4.6e-03); Loss of Catalytic site at S160 (Pr = 0.16 | P = 0.02), ELME000062|ELME000063|ELME000102|PS00008|PS00017,-
MYO7A_HUMAN,R666Q,0.869,Altered Metal binding (Pr = 0.33 | P = 1.7e-03); Gain of Strand (Pr = 0.28 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01); Gain of Catalytic site at E663 (Pr = 0.13 | P = 0.03), ELME000012|ELME000052|ELME000101|PS00005,-
MYO7A_HUMAN,G1497R,0.957,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.2e-03); Loss of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080|ELME000137|PS00001,-
MYO7A_HUMAN,T165M,0.776,Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Methylation at K164 (Pr = 0.21 | P = 5.6e-03); Loss of Catalytic site at S160 (Pr = 0.15 | P = 0.02), ELME000336|PS00008|PS00017,-
MYO7A_HUMAN,S617P,0.895,Loss of Helix (Pr = 0.28 | P = 0.03), ELME000100|ELME000106|ELME000108|ELME000149|ELME000335,-
MYO7A_HUMAN,A2113P,0.946,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04), ELME000085|ELME000136|ELME000159|ELME000197|ELME000328,-
MYO7A_HUMAN,L1122I,0.100,-,-,-
MYO7A_HUMAN,L236Q,0.919,Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 4.3e-03); Altered Metal binding (Pr = 0.27 | P = 6.3e-03); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at R241 (Pr = 0.26 | P = 0.01); Loss of Acetylation at K231 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at K239 (Pr = 0.09 | P = 0.05), ELME000182,-
MYO7A_HUMAN,R1240Q,0.771,Gain of N-linked glycosylation at N1237 (Pr = 0.02 | P = 0.03), ELME000053|ELME000070|ELME000202|PS00001,-
MYO7A_HUMAN,G519V,0.818,, PS00008,-
MYO7A_HUMAN,L651P,0.952,Gain of Allosteric site at F647 (Pr = 0.21 | P = 0.03), ELME000106|ELME000313,-
MYO7A_HUMAN,Y95C,0.914,Altered Ordered interface (Pr = 0.44 | P = 5.7e-04); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Allosteric site at Y97 (Pr = 0.27 | P = 8.5e-03); Loss of Strand (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.25 | P = 8.3e-03); Altered Metal binding (Pr = 0.18 | P = 0.01), ELME000053|ELME000182|ELME000336|PS00007,-
MYO7A_HUMAN,R378S,0.788,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000053|ELME000063|ELME000064|ELME000085|ELME000220|PS00006,-
MYO7A_HUMAN,L1167H,0.924,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.13 | P = 0.03), ELME000146,-
MYO7A_HUMAN,M283I,0.600,Altered Ordered interface (Pr = 0.28 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Gain of Disulfide linkage at C286 (Pr = 0.15 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y278 (Pr = 0.02 | P = 0.04), ELME000182,-
MYO7A_HUMAN,P1467L,0.894,Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Allosteric site at W1466 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000080|ELME000106|ELME000146|ELME000149|ELME000233,-
